The use of antipsychotic medications to treat aggression in youths with autism spectrum disorders (ASD) is based on open-label trials and efficacy studies. There are no studies examining the combined effectiveness of antipsychotic medications and intensive behavioral intervention (IBI) to treat aggression in ASD.
Methods:
Youths with ASD and aggressive behavior received IBI. Medication use remained stable during the study period and was coded into antipsychotic, mood-stabilizing, and nonstimulant attention-deficit/hyperactivity disorder (ADHD)/sleep medication classes. Analysis of covariance (ANCOVA) and survival analyses examined the effects of medication classes on the average number of aggressive behaviors and time to behavior plan success.
Results:
Thirty-two youths (mean age = 11.16, standard deviation [SD] = 3.31, range = 4–16 years, 75% male) with ASD received aggression reduction plans. Of these, 25 youths were taking at least one psychiatric medication (antipsychotic n = 18, mood stabilizing n = 10, and nonstimulant ADHD/sleep n = 12). Aggression dropped substantially following implementation of IBI (p < 0.001; d = 1.70). Antipsychotic medication use predicted significantly fewer sessions to achieve behavior plan success (χ2(1) = 5.67, p = 0.017; d = 0.93). No other medication classes influenced aggressive behavior (largest χ2(1) = 0.16, p = 0.694).
Conclusions:
Behavioral treatment combined with antipsychotic medication was the most effective approach to reducing aggressive behaviors in youths with ASD. Mood-stabilizing and nonstimulant ADHD/sleep medications did not contribute to aggression reduction.
Get full access to this article
View all access options for this article.
References
1.
AccardoP. Risperidone in children with autism and serious behavioral problems. J Pediatr, 142:86–87. 2003.
2.
AllikH, LarssonJO, SmedjeH. Sleep patterns of school-age children with Asperger syndrome or high-functioning autism. J Autism Dev Disord, 36:585–595. 2006.
3.
AmanMG, SinghNN, StewartAW, FieldCJ. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic, 89:485–491. 1985.
4.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th(DMS-IV)Washington (DC): American Psychiatric Association, 1994.
5.
AndersonLT, CampbellM, GregaDM, PerryR, SmallAM, GreenWH. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry, 141:1195–1202. 1984.
6.
BelcherTL. Behavioral treatment vs. behavioral control: A case study. J Devel Phys Disabil, 7:235–241. 1995.
CanitanoR. Self injurious behavior in autism: Clinical aspects and treatment with risperidone. J Neural Transm, 113:425–431. 2006.
9.
CarterAS, BlackDO, TewaniS, ConnollyCE, KadlecMB, Tager-FlusbergH. Sex differences in toddlers with autism spectrum disorders. J Autism Dev Disord, 37:86–97. 2007.
10.
ChezMG, MemonS, HungPC. Neurologic treatment strategies in autism: An overview of medical intervention strategies. Semin Pediatr Neurol, 11:229–235. 2004.
11.
DeppC, LebowitzBD. Clinical trials: Bridging the gap between efficacy and effectiveness. Int Rev Psychiatry, 19:531–539. 2007.
12.
DominickK, DavisN, LainhartJ, Tager-FlusbergH, FolsteinS. Atypical behaviors in children with autism and children with a history of language impairment. Res Dev Disabil, 28:145–162. 2007.
13.
EikesethS, SmithT, JahrE, EldevikS. Intensive behavioral treatment at school for 4- to 7-year-old children with autism. A 1-year comparison controlled study. Behav Modif, 26:49–68. 2002.
14.
EikesethS, SmithT, JahrE, EldevikS. Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: A comparison controlled study. Behav Modif, 32:264–278. 2007.
15.
EldevikS, EikesethS, JahrE, SmithT. Effects of low intensity behavioral treatment for children with autism and mental retardation. J Autism Dev Disord, 36:211–224. 2006.
16.
ErnstE, PittlerMH. Efficacy or effectiveness?J Intern Med, 260:488–490. 2006.
17.
FoxxRM, MeindlJ. The long term successful treatment of the aggressive/destructive behaviors of a preadolescent with autism. Behav Intervent, 22:83–97. 2007.
18.
GartlehnerG, HansenRA, NissmanD, LohrKN, CareyTS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol, 59:1040–1048. 2006.
19.
GeschwindD. Autism: Searching for coherence. Biol Psychiatry, 62:949–950. 2007.
20.
GobbiG, PulvirentiL. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci, 26:340–341. 2001.
21.
Goin-KochelR, MyersB, MacKintoshV. Parental reports on the use of treatments and therapies for children with autism spectrum disorders. Res Autism Spectr Disord, 1:195–209. 2007.
22.
HorriganJP, BarnhillLJ. Risperidone and explosive aggressive autism. J Autism Dev Disord, 27:313–323. 1997.
23.
HowlinP, MagiatiI, CharmanT. Systematic review of early intensive behavior interventions for children with autism. Am J Intellect Develop Disabilities, 114:23–41. 2009.
24.
JensenPS, HinshawSP, SwansonJM, GreenhillLL, ConnersCK, ArnoldLE, AbikoffHB, ElliottG, HechtmanL, HozaB, MarchJS, NewcornJH, SevereJB, VitielloB, WellsK, WigalT. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and applications for primary care providers. J Dev Behav Pediatr, 22:60–73. 2001.
25.
KangJ, SchaferJL. Demystifying double robustness: A comparison of alternative strategies for estimating population means from incomplete data. Statist Sci, 26:523–539. 2007.
26.
KerbeshianJ, BurdL, RandallT, MartsolfJ, JalalS. Autism, profound mental retardation and atypical bipolar disorder in a 33-year-old female with a deletion of 15q12. J Ment Defic Res, 34,Pt 2:205–210. 1990.
27.
KowatchRA, FristadM, BirmaherB, WagnerKD, FindlingRL, HellanderM. Treatment guidelines for children and adolescents with bipolar disorder: Child Psychiatric Workgroup on Bipolar Disorder. J Am Acad Child Adolesc Psychiatry, 44:213–235. 2005.
28.
KratochvilCJ, FindlingRL, McDougleCJ, ScahillL, HamarmanS. Pharmacological management of agitation and aggression in an adolescent with autism. J Am Acad Child Adolesc Psychiatry, 44:829–832. 2005.
29.
LeeDO, OusleyOY. Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 16:737–746. 2006.
30.
LordC, SchoplerE. Differences in sex ratios in autism as a function of measured intelligence. J Autism Dev Disord, 15:185–193. 1985.
31.
LordC, SchoplerE, RevickiD. Sex differences in autism. J Autism Dev Disord, 12:317–330. 1982.
32.
LovaasOI. Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol, 55:3–9. 1987.
33.
LubyJ, MrakotskyC, Meade-StaletsM, BeldenA, HeffelfingerA, WilliamsM, SpitznagelE. Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol, 16:575–587. 2006.
34.
MacDonaldKM, VancayzeeleS, DeblanderA, AbrahamIL. Longitudinal observational studies to study the efficacy-effectiveness gap in drug therapy: Application to mild and moderate dementia. Nurs Clin North Am, 41:105–117vii2006.
35.
MagiatiI, CharmanT, HowlinP. A two-year prospective follow-up stduy of community-based early intensive behavioral intervention and specialist nursery provision for children with autism spectrum disorders. J Child Psychol Psychiatry, 48:803–812. 2007.
36.
MaloneRP, SilviaSS, DelaneyMA, HymanS. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs, 19:923–934. 2005.
37.
MalowBA, CroweC, HendersonL, McGrewSG, WangL, SongY, StoneWL. A sleep habits questionnaire for children with autism spectrum disorders. J Child Neurol, 24:19–24. 2009.
38.
MarchJS, SilvaS, PetryckiS, CurryJ, WellsK, FairbankJ, BurnsB, DominoM, McNultyS, VitielloB, SevereJ. The treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes. Arch Gen Psychiatry, 64:1132–1143. 2007.
39.
MarshburnEC, AmanMG. Factorial validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. J Autism Dev Disord, 22:357–373. 1992.
40.
MatsonJ, BenavidezD, ComptonLS, PaclawskyjT, BaglioC. Behavioral treatment of autistic persons: A review of research from 1980 to the present. Res Dev Disabil, 17:433–465. 1996.
41.
MatsonJL, DixonDR, MatsonML. Assessing and treating aggression in children and adolescents with developmental disabilities: A 20-year overview. Educ Psychol, 25:151–181. 2005.
42.
MatsonJ, LoVulloS, BoisjoliJ, GonzalezM. The behavioral treatment of an 11-year old girl with autism and aggressive behaviors. Clin Case Stud, 7:313–326. 2008.
43.
McClellanJ, WerryJ. Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 36:157–176. 1997.
44.
McClellanJ, KowatchR, FindlingRL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry, 46:107–125. 2007.
45.
McCrackenJT, McGoughJ, ShahB, CroninP, HongD, AmanMG, ArnoldLE, LindsayR, NashP, HollwayJ, McDougleCJ, PoseyD, SwiezyN, KohnA, ScahillL, MartinA, KoenigK, VolkmarF, CarrollD, LancorA, TierneyE, GhumanJ, GonzalezNM, GradosM, VitielloB, RitzL, DaviesM, RobinsonJ, McMahonD. Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314–321. 2002.
46.
McDougleC. Current, emerging therapeutics of autistic disorder, related pervasive developmental disorders. Neuropsychopharmacology: The Fifth Generation of Progress. DavisKL, CharneyD, CoyleJT, NemeroffC. Philadelphia: Lippincott Williams and Wilkins, 2002; 565–576.
47.
McDougleCJ, ScahillL, AmanMG, McCrackenJT, TierneyE, DaviesM, ArnoldLE, PoseyDJ, MartinA, GhumanJK, ShahB, ChuangSZ, SwiezyNB, GonzalezNM, HollwayJ, KoenigK, McGoughJJ, RitzL, VitielloB. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry, 162:1142–1148. 2005.
48.
MunesueT, OnoY, MutohK, ShimodaK, NakataniH, KikuchiM. High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: A preliminary study of 44 outpatients. J Affect Disord, 111:170–175. 2008.
49.
PoseyDJ, WalshKH, WilsonGA, McDougleCJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol, 9:273–276. 1999.
50.
POTS: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 292:1969–1976. 2004.
51.
ProchaskaJO, EversKE, ProchaskaJM, Van MarterD, JohnsonJL. Efficacy and effectiveness trials: examples from smoking cessation and bullying prevention. J Health Psychol, 12:170–178. 2007.
52.
RosenbaumPR, RubinDB. The central role of the propensity score in observational studies for causal effects. Biometrika, 70:41–55. 1983.
53.
RubinDB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol, 66:688–701. 1974.
54.
SanchezLE, AdamsPB, UysalS, HallinA, CampbellM, SmallAM. A comparison of live and videotape ratings: Clomipramine and haloperidol in autism. Psychopharmacol Bull, 31:371–378. 1995.
55.
SchaferJL, GrahamJW. Missing data: Our view of the state of the art. Psycholog Methods, 7:147–177. 2002.
56.
SchaferJL, KangJ. Average causal effects from nonrandomized studies: A practical guide and simulated example. Psycholog Methods, 13:279–313. 2008.
57.
TuchmanR, MosheSL, RapinI. Convulsing toward the pathophysiology of autism. Brain Dev, 31:95–103. 2009.
58.
VercellinoF, ZanottoE, RaveraG, VeneselliE. Open-label risperidone treatment of 6 children and adolescents with autism. Can J Psychiatry, 46:559–560. 2001.
59.
WilhelmS, BuhlmannU, TolinDF, MeunierSA, PearlsonGD, ReeseHE, CannistraroP, JenikeMA, RauchSL. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry, 165:335–341quiz 4092008.
60.
YoungstromEA, BirmaherB, FindlingRL. Pediatric bipolar disorder: Validity, phenomenology, and recommendations for diagnosis Bipolar Disord, 10:194–214. 2008.
